All In Biotech

NDA 021288 · Verity

Trelstar

Triptorelin Pamoate · Intramuscular

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jun 29, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

246

82 Phase 3, 36 recruiting

FAERS reports

2,599

1,873 serious, 532 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2026.

TRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. TRELSTAR is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )

Mechanism: Triptorelin is a synthetic decapeptide agonist analog of gonadotropin releasing hormone (GnRH). Comparative in vitro studies showed that triptorelin was 100-fold more active than native GnRH in stimulating luteinizing hormone release from monolayers of dispersed rat pituitary cells in culture and 20-fold more active than native GnRH in displacing 125 I-GnRH from pituitary receptor sites. In animal studies, triptorelin pamoate was found to have 13‑fold higher luteinizing hormone-releasing activity and 21-fold higher follicle-stimulating hormone-releasing activity compared to the native GnRH.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TRELSTAR · TRIPTORELIN PAMOATE EQ 11.25MG BASE/VIAL · INJECTABLE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Triptorelin Pamoate" as an intervention, any sponsor and status, largest first.

All 246 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death406
  • fatigue128
  • hot flush127
  • inappropriate schedule of product administration110
  • off label use107
  • asthenia89
  • prostatic specific antigen increased89
  • malignant neoplasm progression82
  • product dose omission issue82
  • disease progression78
  • terminal state74
  • drug ineffective73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20055
20067
200716
20087
20095
201019
201133
201253
201328
201447
201570
201657
201758
2018138
2019157
2020221
2021205
2022251
2023268
2024331
2025383
2026237

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trelstar (Triptorelin Pamoate)

2024 spending

$15.3M

Beneficiaries

2,414

6,223 claims

Per beneficiary

$6,352

$2,463.15 per unit

View as table
YearSpending
2020$0
2021$10,920,256
2022$14,688,634
2023$14,231,107
2024$15,333,167

Part B: Trelstar (Triptorelin Pamoate) · HCPCS J3315

2024 spending

$11.4M

Beneficiaries

3,298

7,918 claims

Per beneficiary

$3,447

2024 ASP limit $438.88 per unit

View as table
YearSpending
2020$11,316,962
2021$23,819,755
2022$12,310,846
2023$9,957,976
2024$11,367,888

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Verity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.